Standout Papers
Citation Impact
Citing Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
2005 Standout
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
2008
Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors
2005
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules
2008
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Campylobacter gene polymorphism as a determinant of clinical features of Guillain–Barre syndrome
2005
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
2007
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
2015
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
2006
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
2013 StandoutScienceNobel
Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy
2010
Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
2008
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
2013
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
2008
Cochrane Database of Systematic Reviews
2003 Standout
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
2009
Anti-GT1a IgG in Guillain-Barre syndrome
2002
Hepatocellular carcinoma
2003 Standout
Idiopathic pulmonary fibrosis
2017 Standout
Is IgG anti-GT1a antibody associated with pharyngeal–cervical–brachial weakness or oropharyngeal palsy in Guillain–Barré syndrome?
1998
Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial
2003
Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia
2002
Abnormal expression of apoptosis‐related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma
2003
Cytogenetic, Molecular Genetic, and Clinical Characteristics of Acute Myeloid Leukemia With a Complex Karyotype
2008
Balanced chromosome abnormalities inv(16) and t(15;17) in therapy‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop†
2002
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
2003
Clinical and Epidemiologic Features of Guillain‐Barré Syndrome
1997
Chromosome translocations: dangerous liaisons revisited
2001
Guillain-Barré syndrome after exposure to influenza virus
2010
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
2005
Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation
2007
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome
1998 Standout
Chromatin structural elements and chromosomal translocations in leukemia
2006
Guillain–Barré and Miller Fisher syndromes—new diagnostic classification
2014
A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
1999
Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia
2001
Cytogenetics in acute leukemia
2003
Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia
2009
Guillain-Barré syndrome
2016 Standout
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
2010
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
2010
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
2006
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
2008
High-Resolution Profiling of Histone Methylations in the Human Genome
2007 Standout
Array-based genomic resequencing of human leukemia
2010
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML
2003
Guillain–Barré Syndrome
2012 Standout
Anti–GM1 IgG antibodies induce leukocyte effector functions via Fcγ receptors
2003
The immunobiology of Guillain‐Barré syndromes
2005
Tie2/Angiopoietin-1 Signaling Regulates Hematopoietic Stem Cell Quiescence in the Bone Marrow Niche
2004 Standout
Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML
2008
Cricopharyngeal Botox injection: indications and technique
2006
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
2005
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
2006 Standout
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: A detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24‐color FISH
2002
Mouse models of human AML accurately predict chemotherapy response
2009
Acute myeloid leukaemia
2006
Dynamic RNA Modifications in Gene Expression Regulation
2017 Standout
Subtelomeric chromosome rearrangements are detected using an innovative 12-color FISH assay (M-TEL)
2001
c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia
1999
Cancer genes and the pathways they control
2004 Standout
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup
2002
Miller Fisher anti-GQ1b antibodies: ?-Latrotoxin-like effects on motor end plates
1999
Acute Myeloid Leukemia and the Position of Autologous Stem Cell Transplantation
2007
Acute leukemia during pregnancy
2005
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
2006
Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease
1999
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
2006
‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?*
2003 Standout
Treatment of hepatocellular carcinoma in patients with cirrhosis
1997
Philadelphia Chromosome–Positive Acute Myeloid Leukemia
2007
Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression
2012 StandoutNobel
Biology and management of relapsed acute myeloid leukaemia
2005
Ganglioside GM1 Mimicry inCampylobacterStrains from Sporadic Infections in the United States
1999
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
An investigator‐driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis
2011
11q23 balanced chromosome aberrations in treatment‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop†
2002
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
2006
Molecular genetics in acute myeloid leukemia
2010
Antibodies to GT1a ganglioside in patients with Guillain–Barré syndrome
1998
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
2002 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia
2001
The upper oesophageal sphincter
2005
Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia
2004
Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases
2018 Standout
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
2003
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial
2003
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Guillain-Barré syndrome
1998
Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
2007
MicroRNA signatures in human cancers
2006 Standout
The distribution of CD1 molecules in inflammatory neuropathy
1998
Anti-GQ1b Ganglioside Antibody in Peripheral Nervous System Disorders
2004
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500)
2007
Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia
1999
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
2001
Peripheral neuropathies and anti-glycolipid antibodies
2002
Monoclonal antibodies raised against Guillain-Barré syndrome–associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations
1999
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
2004
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
2002
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
2008
Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy
2009
Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia
2008
The PI3K Pathway in Human Disease
2017 Standout
Electromyography of human cricopharyngeal muscle of the upper esophageal sphincter
2002
Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission
2009
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Pathogenesis of Guillain–Barré syndrome
1999
Realistic Pathologic Classification of Acute Myeloid Leukemias
2001
Outcome of patients with acute myelogenous leukemia after second salvage therapy
2005
Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation
2007
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
2014 Standout
Simultaneous Inference in General Parametric Models
2008 Standout
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
2016 StandoutNobel
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
2010
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
2005 Standout
Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia
2009
Guillain-Barré syndrome
2005 Standout
Unrelated donor bone marrow transplantation using a chemotherapy‐only preparative regimen for adults with high‐risk acute myelogenous leukemia
2006
The cancer genome
2009 StandoutNature
Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission
2005
Advances in understanding and treatment of immune‐mediated disorders of the peripheral nervous system
2004
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
2009 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification
2009
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission
2007
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients
2007
Comparison of Cytogenetic and Molecular Genetic Detection of t(8;21) and inv(16) in a Prospective Series of Adults With De Novo Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2001
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
2006
MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients
2007
Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
2005
Increasing frequency of acute myeloid leukemia complicating Hodgkin's disease: A review
1980
Acute Myeloid Leukemia
2015 Standout
Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia
2002
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
2015
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
6-Thioguanine, Cytarabine, and Daunorubicin (TAD) and High-Dose Cytarabine and Mitoxantrone (HAM) for Induction, TAD for Consolidation, and Either Prolonged Maintenance by Reduced Monthly TAD or TAD-HAM-TAD and One Course of Intensive Consolidation by Sequential HAM in Adult Patients at All Ages With De Novo Acute Myeloid Leukemia (AML): A Randomized Trial of the German AML Cooperative Group
2003
Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype
2008
Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2009
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features
2006
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B
2006
Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia in First or Subsequent Remission: Weighing Prognostic Markers Predicting Relapse and Risk Factors for Non-relapse Mortality
2008
Hematopoietic cell transplantation–specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences
2007
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
2009 Standout
Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome
1998
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
2007
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
2003
Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study
2005
Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
2003
Prognostic value of cytogenetic findings in adults with acute myeloid leukemia.
2000
Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
2006
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
2003
Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization
2021 Standout
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
2001
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
2001
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
2006
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
2005
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
2005
Treatment of Hepatocellular Carcinoma Associated with Cirrhosis in the Era of Liver Transplantation
1998
CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations
2004
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
2002
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
2001 Standout
How I treat refractory and early relapsed acute myeloid leukemia
2015
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)
2002
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup
2003
A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements.
2000
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
2002
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
2005
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
2005
Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype
2005
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication
2009
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial
2002
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics
2006
Preceding infections, immune factors, and outcome in Guillain–Barre syndrome
2001
Chromosomal translocations: revisited yet again
2008
Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group
2007
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes
2003
Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461
2004
Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations
2010
Disclosure of Candidate Genes in Acute Myeloid Leukemia With Complex Karyotypes Using Microarray-Based Molecular Characterization
2006
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Management of Acute Myelogenous Leukemia in the Elderly
2003
Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461
2004
Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease.
1987 StandoutNobel
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis
2010
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
2000
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
2005
Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup
2004
Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2008
Comparison of Cytogenetic and Molecular Cytogenetic Detection of Chromosome Abnormalities in 240 Consecutive Adult Patients With Acute Myeloid Leukemia
2002
Effects of Dihydrocodeine, Alcohol, and Caffeine on Breathlessness and Exercise Tolerance in Patients with Chronic Obstructive Lung Disease and Normal Blood Gases
1981
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
2007
Multistep Carcinogenesis: A Chain Reaction of Aneuploidizations
2003
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
2005
Works of John Rees being referenced
Glioblastoma multiforme: radiologic-pathologic correlation.
1996
Small Hepatocellular Carcinomas in Cirrhotic Explant Livers: Identification by Macroscopic Examination and Lipiodol Localization
1997
Sirolimus-Induced Pneumonitis: Three Cases and a Review of the Literature
2003
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial
2002
Botulinum toxin for cricopharyngeal dysphagia: case reports of CT-guided injection.
1997
Haemoptysis and non-organic upper airways obstruction in a patient with previously undiagnosed Ehlers-Danlos syndrome
1981
Reactivity of serum IgG anti-GM1 ganglioside antibodies with the lipopolysaccharide fractions of Campylobacter jejuni isolates from patients with Guillain–Barré syndrome (GBS)
1997
Myeloma in a Case of Hodgkin’s Disease
1974
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
1998
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
1998 Standout
Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides.
1996